PHOENIX — Arizona has administered its 2 millionth dose of COVID-19 vaccine as the state and local partners work to get the currently limited supply into arms as quickly as possible, including highly targeted efforts in underserved areas. Continue reading
Datavant and the Cerebral Palsy Research Network Announce Partnership to Enable Investigation of Genetic Basis of Cerebral PalsyContinue reading
Arizona State University has announced the appointment of Jeffrey Kordower as the founding director of the ASU-Banner Neurodegenerative Disease Research Center and endowed chair as The Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute.Continue reading
Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts
The Critical Path to Therapeutics for the Ataxias will optimize clinical trials for inherited ataxias
TUCSON, Ariz., February 26, 2021 — Critical Path Institute (C-Path) today announced the launch of the Critical Path to Therapeutics for the Ataxias (CPTA) Consortium, a public-private partnership focused on optimizing clinical trials for inherited ataxias. CPTA is a collaborative effort between C-Path, Ataxia Global Initiative, the National Ataxia Foundation, Ataxia UK and key partners in the industry and academic research communities, including Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Roche Pharmaceuticals, Servier Group, Triplet Therapeutics, uniQure, and Vico Therapeutics.Continue reading
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper (White Paper Two), regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing (RNA-Seq). HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.Continue reading
Five Phoenix, two Tucson firms to receive personalized learning plan, other benefitsContinue reading
The joint partnership between Life365 and VectorCare will enable healthcare organizations to create more efficient workflows and accelerate the deployment of digital health solutions. The companies saw an opportunity to provide remote health monitoring services to effectively treat and manage patients in their homes.
If successful, non-invasive method could transform detection and treatment outcomesContinue reading
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders